Please login to the form below

Not currently logged in
Email:
Password:

Antisense secures funding

Germany-based Antisense Pharma has secured new funding as it begins an international trial of its pancreatic cancer treatment

Antisense Pharma has completed its latest round of fundraising, with its main investor MIG Funds 2, 3 and 9, as well as GAF increasing their share capital by approximately €8m.

The German company has launched a second international clinical trial of trabedersen, a second-line treatment for pancreatic cancer. Michael Motschmann, chief executive of MIG Verwaltungs, said: "Trabedersen could give new hope to patients suffering from this extremely aggressive type of cancer and open up a greatly needed but thus far completely vacant market niche along with its corresponding high revenue potential.

"At the same time, this means a risk reduction for the development of trabedersen, as this medication now has several marketing opportunities if the trials are successful. Furthermore, there is a potential for added value since new markets can be opened up."

The company has also announced that it chief executive Dr Karl-Hermann Schlingensiepen has moved to an advisory position. Dr Hubert Heinrichs, managing director and chief medical officer of Antisense Pharma, will assume the position as acting CEO.

6th July 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
M&F Health

M&F Health is a full service communications agency, dedicated to the health and wellbeing sector. We are an independent amongst...

Latest intelligence

Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....

Infographics